A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

NCT02358031 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

882

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Head and Neck Cancer
Metastatic Head and Neck Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: 5-FU
BIOLOGICAL: Cetuximab

Sponsor

Merck Sharp & Dohme LLC